Please use this identifier to cite or link to this item:
|Title:||Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial||Authors:||Bisogno, Gianni
De Salvo, Gian Luca
Gallego Melcón, Soledad
Merks, Johannes H
|Issue Date:||Nov-2019||Journal:||The Lancet. Oncology||Abstract:||
For more than three decades, standard treatment for rhabdomyosarcoma in Europe has included 6 months of chemotherapy. The European paediatric Soft tissue sarcoma Study Group (EpSSG) aimed to investigate whether prolonging treatment with maintenance chemotherapy would improve survival in patients with high-risk rhabdomyosarcoma.
|Appears in Collections:||Articles|
Show full item record
checked on May 2, 2021
checked on Sep 1, 2020
WEB OF SCIENCETM
checked on Dec 6, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.